Enterprise Value
74.13M
Cash
164.3M
Avg Qtr Burn
-25.39M
Short % of Float
1.46%
Insider Ownership
3.70%
Institutional Own.
63.54%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ixo-vec (ADVM-022) (AAV.7m8-aflibercept) Details Wet age-related macular degeneration , Age-related macular degeneration, Eye disease | Phase 2 Interim update | |
ADVM-022 (AAV.7m8 Afiblercept) Details Diabetes, Eye disease , Diabetic macular edema | Failed Discontinued |